This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alcalá, L.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alcalá, L.
Right arrow Articles by Bouza, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 416-417, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.416-417.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

Luis Alcalá,* María Jesús Ruiz-Serrano, Cristina Pérez-Fernández Turégano, Darío García de Viedma, Marisol Díaz-Infantes, Mercedes Marín-Arriaza, and Emilio Bouza

Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario "Gregorio Marañón," Madrid, Spain

Received 24 May 2002/ Returned for modification 30 July 2002/ Accepted 2 October 2002

We evaluated 117 isolates of Mycobacterium tuberculosis for susceptibility to linezolid by the proportion and E-test methods. Linezolid showed high in vitro activity, with all the strains inhibited by <=1 µg of the drug per ml. E-test MICs were at least 4 dilutions lower than their equivalents by the standard proportion method.

* Corresponding author. Mailing address: Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario "Gregorio Marañón," Doctor Esquerdo, 46, 28007 Madrid, Spain. Phone: (34) 91 586 8453. Fax: (34) 91 504 4906. E-mail: luisalcala{at}efd.net.

Antimicrobial Agents and Chemotherapy, January 2003, p. 416-417, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.416-417.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Daley, C. L. (2010). Update in Tuberculosis 2009. Am. J. Respir. Crit. Care Med. 181: 550-555 [Full Text]  
  • McGee, B., Dietze, R., Hadad, D. J., Molino, L. P. D., Maciel, E. L. N., Boom, W. H., Palaci, M., Johnson, J. L., Peloquin, C. A. (2009). Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 53: 3981-3984 [Abstract] [Full Text]  
  • Williams, K. N., Brickner, S. J., Stover, C. K., Zhu, T., Ogden, A., Tasneen, R., Tyagi, S., Grosset, J. H., Nuermberger, E. L. (2009). Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 180: 371-376 [Abstract] [Full Text]  
  • Migliori, G. B., Eker, B., Richardson, M. D., Sotgiu, G., Zellweger, J-P., Skrahina, A., Ortmann, J., Girardi, E., Hoffmann, H., Besozzi, G., Bevilacqua, N., Kirsten, D., Centis, R., Lange, C., for the TBNET Study Group, (2009). A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34: 387-393 [Abstract] [Full Text]  
  • Williams, K. N., Stover, C. K., Zhu, T., Tasneen, R., Tyagi, S., Grosset, J. H., Nuermberger, E. (2009). Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. Antimicrob. Agents Chemother. 53: 1314-1319 [Abstract] [Full Text]  
  • Yew, W. W., Leung, C. C. (2009). Update in Tuberculosis 2008. Am. J. Respir. Crit. Care Med. 179: 337-343 [Full Text]  
  • Guy, E. S., Mallampalli, A. (2008). Review: Managing TB in the 21st century: existing and novel drug therapies. Ther Adv Respir Dis 2: 401-408 [Abstract]  
  • Coban, A. Y., Bilgin, K., Uzun, M., Akgunes, A., Yusof, A., Durupinar, B. (2008). Comparative Study for Determination of Mycobacterium tuberculosis Susceptibility to First- and Second-Line Antituberculosis Drugs by the Etest Using 7H11, Blood, and Chocolate Agar. J. Clin. Microbiol. 46: 4095-4098 [Abstract] [Full Text]  
  • Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., Palaci, M., Johnson, J. L. (2008). Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 178: 1180-1185 [Abstract] [Full Text]  
  • Huang, T.-S., Liu, Y.-C., Sy, C.-L., Chen, Y.-S., Tu, H.-Z., Chen, B.-C. (2008). In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years. Antimicrob. Agents Chemother. 52: 2226-2227 [Abstract] [Full Text]  
  • Park, I-N., Hong, S.-B., Oh, Y.-M., Kim, M.-N., Lim, C.-M., Lee, S. D., Koh, Y., Kim, W. S., Kim, D. S., Kim, W. D., Shim, T. S. (2006). Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 58: 701-704 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Andries, K., Jarlier, V. (2006). Bactericidal Activities of R207910 and Other Newer Antimicrobial Agents against Mycobacterium leprae in Mice. Antimicrob. Agents Chemother. 50: 1558-1560 [Abstract] [Full Text]  
  • Vera-Cabrera, L., Castro-Garza, J., Rendon, A., Ocampo-Candiani, J., Welsh, O., Choi, S. H., Blackwood, K., Molina-Torres, C. (2005). In Vitro Susceptibility of Mycobacterium tuberculosis Clinical Isolates to Garenoxacin and DA-7867. Antimicrob. Agents Chemother. 49: 4351-4353 [Abstract] [Full Text]  
  • Fortun, J., Martin-Davila, P., Navas, E., Perez-Elias, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gomez-Mampaso, E., Moreno, S. (2005). Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56: 180-185 [Abstract] [Full Text]  
  • Guna, R., Munoz, C., Dominguez, V., Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J.-V., Borras, R. (2005). In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 55: 950-953 [Abstract] [Full Text]  
  • Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J. V., Garcia-Domenech, R., Munoz, C., Guna, R., Borras, R. (2005). Search of Chemical Scaffolds for Novel Antituberculosis Agents. J Biomol Screen 10: 206-214 [Abstract]  
  • Griffith, D. E. (2004). Treatment of Multidrug-resistant Tuberculosis: Should You Try This at Home?. Am. J. Respir. Crit. Care Med. 169: 1082-1083 [Full Text]  
  • Brown-Elliott, B. A., Crist, C. J., Mann, L. B., Wilson, R. W., Wallace, R. J. Jr. (2003). In Vitro Activity of Linezolid against Slowly Growing Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 47: 1736-1738 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»